medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2017, Number 2-3

Next >>

Rev Mex Periodontol 2017; 8 (2-3)

Determination of the concentration of IL-23 and the soluble receptor to IL-17 (IL-17RA) in serum and plasma of patients with chronic and aggressive periodontitis: a pilot study

Peña-Echeverría PA, Rodríguez-Montaño R, Ruiz-Gutiérrez AC, Martínez-Rodríguez VMC, Gómez-Meda BC, Cervantes-Cabrera JJ, Guerrero-Velázquez C

Language: Spanish
References: 40
Page: 46-53
PDF size: 321.08 Kb.


ABSTRACT

Background: Chronic periodontitis (CP) is associated with metabolic disorders, and aggressive periodontitis (AP), with family aggregation. Both periodontitis have a strong immune-inflammatory response and culminate in the destruction of alveolar bone. IL-23 and IL-17, as well as their receptors (IL-23R, IL-2317R), play a fundamental role in the immunopathogenesis of periodontitis. In this regard, it has been described that IL-17 and IL-23 increase in PC patients compared to healthy subjects (HS), but in PA, IL-23 has not been determined. On the other hand, it is known that soluble IL23R (IL-23Rs) is elevated in the serum and plasma of patients with PC and PA compared to SS. But the soluble receptor to IL-17 (IL-17RAs) has not been determined in chronic and aggressive periodontitis. Objective: To measure the levels of IL-23 and IL-17RAs in serum and plasma of patients with PC, PA and SS. Material and methods: Serum and plasma were collected by venous puncture from HS (n = 7), patients with CP (n = 7) and PA (n = 7). Serum and plasma were frozen at -70 oC until the analysis of IL-23 and IL-17RAs by the ELISA technique took place. Results: We found a higher concentration of IL-23 in the serum and plasma of patients with PA compared to patients with PC (p = 0.03). We observed lower concentrations of IL-17RA in the serum and plasma of patients with PC versus SS (p = 0.04) and PA compared to HS [serum (p = 0.05) plasma (p = 0.03). Conclusions: We detected an increase in IL-23 in patients with BP and a decrease in IL-17RAs in patients with PC and PA. In general, we found lower concentrations of IL-23 and IL-17RAs than in plasma in all study subjects.


REFERENCES

  1. Petersen PE, Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J Periodontol. 2005; 76 (12): 2187-3193.

  2. Craig RG, Pernat AM, Pecoits-Filho R, Levin NW, Kotanko P. Periodontal diseases and systemic inflammation. Semin Dial. 2013; 26 (1): 23-38.

  3. Lucarini G, Tirabassi G, Zizzi A, Balercia G, Quaranta A, Rubini C et al. Uncoupling of vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) in gingival tissue of type 2 diabetic patients. Inflammation. 2016; 39 (2): 632-642.

  4. Zizzi A, Tirabassi G, Aspriello SD, Piemontese M, Rubini C, Lucarini G. Gingival advanced glycation end-products in diabetes mellitus-associated chronic periodontitis: an immunohistochemical study. J Periodontal Res. 2013; 48 (3): 293-301.

  5. Piemontese M, Aspriello SD, Rubini C, Ferrante L, Procaccini M. Treatment of periodontal intrabony defects with demineralized freeze-dried bone allograft in combination with platelet-rich plasma: a comparative clinical trial. J Periodontology. 2008; 79 (5): 802-810.

  6. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999; 4 (1): 1-6.

  7. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 19; 366 (9499): 1809-1020.

  8. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6 (11): 1123-1132.

  9. Abdi K, Singh NJ, Spooner E, Kessler BM, Radaev S, Lantz L et al. Free IL-12p40 monomer is a polyfunctional adaptor for generating novel IL-12-like heterodimers extracellularly. J Immunol. 2014; 92 (12): 6028-6036.

  10. Paunovic V, Carroll HP, Vandenbroeck K, Gadina M. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL) -12, -17, -23 and -27 in autoinmmunity. Rheumatology (Oxford) 2008; 47 (6): 771-776.

  11. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011; 12 (3): 247-254.

  12. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001; 194 (4): 519-527.

  13. Liu S, Desharnais J, Sahasrabudhe PV, Jin P, Li W, Oates BD et al. Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide. Sci Rep. 2016; 6: 26071.

  14. Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013; 64 (2): 477-485.

  15. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal. 2013; 25 (12): 2335-2347.

  16. Ruggeri RM, Saitta S, Cristani M, Giovinazzo S, Tigano V, Trimarchi F et al. Serum interleukin-23 (IL-23) is increased in Hashimoto’s thyroiditis. Endocr J. 2014; 61 (4): 359-363.

  17. Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012; 304 (6): 465-469.

  18. Przepiera-Bę dzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediators Inflamm. 2015; 2015: 785705.

  19. Gümüş P, Buduneli E, Bıyıkoğlu B, Aksu K, Saraç F, Nile C et al. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin 17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease. J Periodontol. 2013; 84 (11): 1627-1637.

  20. Lester SR, Bain JL, Johnson RB, Serio FG. Gingival concentrations of interleukin-23 and -17 at healthy sites and at sites of clinical attachment loss. Journal of Periodontology. 2007; 78 (8): 1545-1550.

  21. Himani GS, Prabhuji ML, Karthikeyan BV. Gingival crevicular fluid and interleukin-23 concentration in systemically healthy subjects: their relationship in periodontal health and disease. J Periodontal Res. 2014; 49 (2): 237-245.

  22. Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol. 2005; 32 (4): 369-374.

  23. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol. 2004; 75(1): 37-43.

  24. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta VM, Valenzuela MA et al. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol. 2005; 32 (4): 383-389.

  25. Ruiz-Gutiérrez AC, Herrera-Mora MC, Zamora-Pérez AL, Meléndez-Ruiz JL, Martínez-Rodríguez VMC, Guerrero-Velázquez C. Determinación de los niveles de IL-17 en el líquido crevicular gingival de pacientes con periodontits crónica y agresiva. Rev Mex Periodontol. 2014; 5 (2): 2014; 46-50.

  26. Mitani A, Niedbala W, Fujimura T, Mogi M, Miyamae S, Higuchi N et al. Increased expression of interleukin (IL)-35 and IL-17, but not IL-27, in gingival tissues with chronic periodontitis. J Periodontol. 2015; 86 (2): 301-309.

  27. Liukkonen J, Gürsoy UK, Pussinen PJ, Suominen AL, Könönen E. Salivary concentrations of interleukin (IL)-1β, IL-17A, and IL-23 vary in relation to periodontal status. J Periodontol. 2016; 87 (12): 1484-1491.

  28. Cifcibasi E, Koyuncuoglu C, Ciblak M, Badur S, Kasali K, Firatli E et al. Evaluation of local and systemic levels of interleukin-17, interleukin-23, and myeloperoxidase in response to periodontal therapy in patients with generalized aggressive periodontitis. Inflammation. 2015; 38 (5): 1959-1968.

  29. Fu QY, Zhang L, Duan L, Qian SY, Pang HX. Correlation of chronic periodontitis in tropical area and IFN-gamma, IL-10, IL-17 levels. Asian Pac J Trop Med. 2013; 6 (6): 489-492.

  30. Rivadeneyra-Burgos C, Rodríguez-Montaño R, Ruiz-Gutiérrez AC, Rodríguez-Martínez VC, Meléndez-Ruiz JL, Pita-López ML et al. Determinación de los niveles del receptor soluble de IL-23 en suero y plasma de pacientes con periodontitis crónica y agresiva. Rev Mex Periodontol. 2017; 8 (1): 5-10.

  31. Cantín M. Declaración de Helsinki de la Asociación Médica Mundial: Principios éticos para las investigaciones médicas en seres humanos. Revisando su última versión. Int J Med Surg Sci. 2013; 1 (4): 339-346, 2014.

  32. Löe H. The gingival index, the plaque index and the retention index systems. J Periodontol. 1967; 38 (6): 610-616.

  33. Duarte PM, da Rocha M, Sampaio E, Mestnik MJ, Feres M, Figueiredo LC et al. Serum levels of cytokines in subjects with generalized chronic and aggressive periodontitis before and after non-surgical periodontal therapy: a pilot study. J Periodontol. 2010; 81 (7): 1056-1063.

  34. Ohyama H, Kato-Kogoe N, Kuhara A, Nishimura F, Nakasho K, Yamanegi K et al. The involvement of IL-23 and the Th17 pathway in periodontitis. J Dent Res. 2009; 88 (7): 633-638.

  35. Kan SH, Mancini G, Gallagher G. Identification and characterization of multiple splice forms of the human interleukin-23 receptor alpha chain in mitogen-activated leukocytes. Genes Immun. 2008; 9 (7): 631-639.

  36. Franke M, Schröder J, Monhasery N, Ackfeld T, Hummel TM, Rabe B et al. Human and murine interleukin 23 receptors are novel substrates for A disintegrin and metalloproteases ADAM10 and ADAM17. J Biol Chem 2016; 291 (20): 10551-10561.

  37. Mesa F, Pozo E, O’Valle F, Puertas A, Magan-Fernández A, Rosel E et al. Relationship between periodontal parameters and plasma cytokine profiles in pregnant woman with preterm birth or low birth weight. Clin Oral Investig. 2016; 20 (4): 669-674.

  38. Sohda M, Misumi Y, Tashiro K, Yamazaki M, Saku T, Oda K. Identification of a soluble isoform of human IL-17RA generated by alternative splicing. Cytokine. 2013; 64 (3): 642-645.

  39. Rosenberg-Hasson Y, Hansmann L, Liedtke M, Herschmann I, Maecker HT. Effects of serum and plasma matrices on multiplex immunoassays. Immunol Res. 2014; 58 (2-3): 224-233.

  40. Lee JE, Kim JW, Han BG, Shin SY. Impact of whole-blood processing conditions on plasma and serum concentrations of cytokines. Biopreserv Biobank. 2016; 14 (1): 51-55.




2020     |     www.medigraphic.com